EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria

Aldo A Acosta-Medina iD, Meera Sridharan iD, Ronald S Go, Ann M Moyer, Nelson Leung iD, Maria Alice V Willrich iD, Robert Wolf, Rabee Kassis, Almothana Manasrah, Mira A Kohorst, Urshila Durani iD, Aasiya Matin und 8 weitere

American Journal of Hematology · 2025-05 · 100 (5) · 830-839

DOI: 10.1002/ajh.27651 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift American Journal of Hematology, online erschienen am 06.03.2025. Verfasst von Aldo A Acosta-Medina und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ASH Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transplant‐associated thrombotic microangiopathy (TA‐TMA) is an endothelial dysfunction syndrome observed after allogeneic hematopoietic cell transplant (alloHCT). Our aim was to externally validate the impact of high‐risk features on the clinical outcomes of adult patients meeting the updated TA‐TMA harmonizing criteria. Between 2005 and 2022, 99 patients were diagnosed with TA‐TMA at Mayo Clinic Rochester (incidence 6.2%) after a median of 137 days post alloHCT (IQR: 34–283 days). The development of TA‐TMA was associated with an inferior overall survival posttransplant (HR: 3.8, 95% CI: 2.97–4.72). High‐risk features, including concomitant infection, acute graft‐versus‐host disease (GVHD), and organ dysfunction, were associated with poor survival, while LDH elevation was not associated with inferior outcomes. The most common treatment strategy for TA‐TMA was discontinuation of calcineurin or mTOR inhibitors in 80 (81%) patients. Thirty (37.5%) patients experienced worsening of GVHD with this strategy, of which 26 (86.7%) patients had died at last follow‐up. The most common cause of death among these patients was worsening GVHD (69%; n = 18), followed by infection (11%; n = 3), disease relapse (8%; n = 2), other/unknown causes (8%; n = 2), or TA‐TMA (4%; n = 1). Objective response rate (ORR) to initial treatment for the cohort was 56.6%. Eculizumab was used in 11 patients with an observed ORR of 70%, including 5 complete responses. In conclusion, TA‐TMA remains a significant contributor to non‐relapse mortality and is associated with worse survival following alloHCT. Not all high‐risk features, particularly LDH elevation, have consistently demonstrated a negative impact in adult cohorts. Patients with TA‐TMA may benefit from immune suppression dose adjustment, rather than a discontinuation, and the addition of complement‐directed therapy, particularly among high‐risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesHematopoietic Stem Cell TransplantationHumansMaleFemaleAdultMiddle AgedGraft vs Host DiseaseRisk FactorsAgedTreatment OutcomeAntibodies, Monoclonal, HumanizedRetrospective Studies

Stichwörter der Autor:innen

allogeneic transplantationcomplement inhibitorrisk assessmentthrombotic microangiopathy

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pharmacy Services, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Aldo A Acosta-Medina, Meera Sridharan, Nelson Leung, Maria Alice V Willrich, Urshila Durani, Mehrdad Hefazi, Saad J Kenderian, Abhishek A Mangaonkar, Mithun V Shah, Mark R Litzow

Förderung

  • ASH Foundation

Zitieren

APA

Acosta-Medina, A. A., Sridharan, M., Go, R. S., Moyer, A. M., Leung, N., Willrich, M. A. V., Wolf, R., Kassis, R., Manasrah, A., Kohorst, M. A., Durani, U., Matin, A., Hefazi, M., Kenderian, S. J., Mangaonkar, A. A., Shah, M. V., Litzow, M. R., Hogan, W. J., Dingli, D., & Alkhateeb, H. B. (2025). Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria. American Journal of Hematology, 100(5), 830-839. https://doi.org/10.1002/ajh.27651

Vancouver

Acosta-Medina AA, Sridharan M, Go RS, Moyer AM, Leung N, Willrich MAV, et al. Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria. American Journal of Hematology. 2025;100(5):830-839. doi:10.1002/ajh.27651

BibTeX
@article{AcostaMedina2025,
  author = {Acosta-Medina, Aldo A and Sridharan, Meera and Go, Ronald S and Moyer, Ann M and Leung, Nelson and Willrich, Maria Alice V and Wolf, Robert and Kassis, Rabee and Manasrah, Almothana and Kohorst, Mira A and Durani, Urshila and Matin, Aasiya and Hefazi, Mehrdad and Kenderian, Saad J and Mangaonkar, Abhishek A and Shah, Mithun V and Litzow, Mark R and Hogan, William J and Dingli, David and Alkhateeb, Hassan B},
  title = {Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {5},
  pages = {830--839},
  doi = {10.1002/ajh.27651}
}
Kostenlos starten →